Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 1/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.46 |
| ▸ | CD38 | P28907 | 7/20 | 0.45 |
| ▸ | PARP1 | P09874 | 9/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | KCNK13 | Q9HB14 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204220 | 0.89 | DHODH (0.43) | CDK1CDK4CDK2 | |
| SCHEMBL5205486 | 0.88 | KCNK13 (0.36) | PKN1PKN2CD38CA5ACDK1 | |
| SCHEMBL5202059 | 0.86 | EED (0.40) | PKN1PKN2CD38CDK1CDK4 | |
| SCHEMBL5206750 | 0.85 | PKN1 (0.41) | PKN1PKN2CD38 | |
| SCHEMBL5201109 | 0.83 | MAPT (0.35) | PKN1PKN2CD38CDK1CDK4 | |
| SCHEMBL5202503 | 0.82 | GNRHR (0.35) | PKN1PKN2CD38CDK1CDK4 | |
| SCHEMBL5201972 | 0.81 | KCNK13 (0.42) | CDK1CDK4CDK2KCNK13 | |
| SCHEMBL5201022 | 0.81 | TLR8 (0.39) | CA5ACDK1CDK4CDK2KCNK13 | |
| SCHEMBL5203544 | 0.79 | TLR8 (0.41) | KCNK13 | |
| SCHEMBL5202583 | 0.79 | TP53 (0.39) | CDK1CDK4CDK2KCNK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210336-B1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | US HEALTH (US) | 2007-04-25 | — | — | EP | disclosed |
| US-6894068-B2 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030191160-A1 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | MICHEJDA CHRISTOPHER J (US) | 2003-10-09 | — | — | US | disclosed |
| EP-1210336-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6369235-B1 | INHIBITORS OF HIV REVERSE TRANSCRIPTION FOR TREATMENT OF AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-04-09 | — | — | US | disclosed |
| WO-2001014343-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191160-A1 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | SAMHD1, DUT, TYMP | PKN1 2649/4885PKN2 2724/4885CD38 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.